BBIO Stock — BridgeBio Pharma Inc.: Cash, EV, Pipeline

What they do

A New Type of Biopharmaceutical Company BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.

Source: 10-K FY2025 via SEC EDGAR

Share price

$78.27

Market cap

$15,233.4M

Cash

$1,538.8M

Enterprise value

$17,244.7M

Balance sheet

Cash	$1,538.8M
Debt	$2,630.1M
Royalty-sale liability	$920.1M
Net cash	-$1,091.2M
Enterprise value	$17,244.7M
Basic shares	194.8M shares
Fully diluted shares	259.4M shares
Fully diluted market cap	$20,305.2M
Cash per share	$7.90
Quarterly burn	$71.1M
Cash runway	21.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Royalty-sale liability as of 2026-09-30 (10-Q); included in enterprise value.

Share structure

Common

195.3M

Pre-funded warrants

0.0M

Options

10.0M

RSUs

9.5M

Warrants

0.0M

Converts

37.8M

Conv preferred

6.8M

ESPP reserve

—

FDSO

259.4M

Cap table as of 2026-06-30.

Price history

Loading BBIO daily closes…

Loading price history…

Next catalyst

infigratinib · Est. Nov 14, 2026 · half midpoint · guided Now

Recently reported

Infigratinib Phase 3 Positive · 2026-10-06

achondroplasia

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 14, 2026 Now half midpoint	infigratinib ACCEL Phase 2 program update in hypochondroplasia	Phase 2	hypochondroplasia	2H 2026
GUIDEDNov 27, 2026 in 13d	BBP-418 NDA PDUFA for limb-girdle muscular dystrophy	Not disclosed	limb-girdle muscular dystrophy	November 27, 2026
GUIDEDMay 8, 2027 in 6 mo	encaleret NDA PDUFA	Not disclosed	Not disclosed	May 8, 2027
Aug 12 - Sep 23 in 9 mo	AG10	Phase 2	Amyloid Cardiomyopathy	—
Feb 12 - Mar 25 in 15 mo	Encaleret	Phase 3	Hypoparathyroidism; Chronic Hypoparathyroidism	—
May 27 - Jul 8 in 19 mo	Acoramidis (AG10)	Phase 3	Amyloid Cardiomyopathy, Transthyretin-Related	—
Jan 12 - Feb 23 in 26 mo	Encaleret	Phase 3	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	—
Nov 12 - Dec 24 in 61 mo	Acoramidis	Phase 3	Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis	—
Jul 12 - Aug 23 in 118 mo	Infigratinib	Phase 2	Hypochondroplasia	—
Dec 13, 2037 - Jan 24, 2038 in 135 mo	Acoramidis (AG10)	Phase 3	Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Attruby

Approved · Active Modality: oral small molecule

Aliases AG10, Beyonttra

Target TTR (transthyretin)

Indications

ATTR cardiomyopathy (ATTR-CM) (Approved)

Status note Next-generation oral small molecule near-complete TTR stabilizer. FDA approved November 22, 2024 for cardiomyopathy of wild-type or variant ATTR amyloidosis; EC approved February 10, 2025 (as Beyonttra) for ATTR-CM.

BBP-418

Phase 3 · Active Modality: oral small molecule

Target FKRP

Indications

limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (Phase 3)

Catalysts

— November 27, 2026

Status note NDA submitted to FDA March 30, 2026; accepted with Priority Review. Designed to supply supra-physiological levels upstream to drive residual activity of the mutant FKRP enzyme.

encaleret

Phase 3 · Active Modality: oral small molecule

Target CaSR (calcium-sensing receptor)

Indications

autosomal dominant hypocalcemia type 1 (ADH1) (Phase 3)
chronic hypoparathyroidism (CHP) (Stage not disclosed)

Catalysts

— May 8, 2027

Status note Negative allosteric modulator of the calcium-sensing receptor. NDA submitted to FDA May 12, 2026 and accepted for filing.

low-dose infigratinib

Phase 3 · Active Modality: oral small molecule

Target FGFR1-3

Indications

achondroplasia (Phase 3)
hypochondroplasia (Phase 3)

Status note Selective FGFR1-3 tyrosine kinase inhibitor; gain-of-function FGFR3 mutations cause achondroplasia/hypochondroplasia. NDA submitted to FDA for achondroplasia; ongoing Phase 2 and Phase 3 trials.

BBP-812

Phase 1 · Active Modality: gene therapy (IV AAV9)

Indications

Canavan disease (Phase 1)

Status note Phase 1/2 CANaspire study ongoing; designed as a single registrational study using a biomarker for accelerated approval. Orphan, Fast Track, RMAT and Rare Pediatric Disease designations from FDA.

antibody deplete program

Stage not disclosed · Active Modality: antibody

Indications

ATTR-CM (Stage not disclosed)

Status note Company references a new antibody deplete program for ATTR-CM; clinical timeline referenced in filing but no named candidate or stage stated.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06873035	Phase 3	Enrolling by invitation	Sponsor	BBIO	—	Hypochondroplasia	—
NCT07805356	Phase 3	Not yet recruiting	Sponsor	BBIO	—	Hypoparathyroidism; Chronic Hypoparathyroidism	—
NCT04988386	Phase 3	Active, not recruiting	Sponsor	BBIO	—	Amyloid Cardiomyopathy, Transthyretin-Related	—
NCT07080385	Phase 3	Recruiting	Sponsor	BBIO	—	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	—
NCT06563895	Phase 3	Recruiting	Sponsor	BBIO	—	Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis	—
NCT07116473	Phase 3	Not yet recruiting	Sponsor	BBIO	—	Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy	—
NCT05680818	Phase 3	Active, not recruiting	Sponsor	BBIO	—	Autosomal Dominant Hypocalcemia (ADH)	—
NCT03536767	Phase 2	Active, not recruiting	Sponsor	BBIO	—	Amyloid Cardiomyopathy	—
NCT07169279	Phase 2	Recruiting	Sponsor	BBIO	—	Achondroplasia	—
NCT05145010	Phase 2	Enrolling by invitation	Sponsor	BBIO	—	Achondroplasia	—
NCT07393373	Phase 2	Enrolling by invitation	Sponsor	BBIO	—	Hypochondroplasia	2H 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)
NCT06410976	Not disclosed	Recruiting	Sponsor	BBIO	—	Hypochondroplasia	—

Sponsor-matched active trials from ClinicalTrials.gov (14 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 17 active trials for QED Therapeutics, a BridgeBio company on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Aisling Capital	4,589,611	-500,000	72.48%	2026-08-13
Frazier Life Sciences	1,548,139	-1,900,000	2.51%	2026-08-14
Cormorant Asset Management	550,000	-300,000	2.10%	2026-08-14
ADAR1 Capital Management	271,689	+82,397	1.25%	2026-08-14
Sphera Biotech	245,346	+100	2.61%	2026-08-14
Ikarian Capital	57,417	-102,703	0.70%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

BBIO — BridgeBio Pharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

BBIO — BridgeBio Pharma Inc.